PubMed Journals Articles About "Testing Immune Hotspots Predict Risk That Breast Cancer" - Page: 3 RSS

01:27 EDT 22nd October 2018 | BioPortfolio

Testing Immune Hotspots Predict Risk That Breast Cancer PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Testing Immune Hotspots Predict Risk That Breast Cancer articles that have been published worldwide.

More Information about "Testing Immune Hotspots Predict Risk That Breast Cancer" on BioPortfolio

We have published hundreds of Testing Immune Hotspots Predict Risk That Breast Cancer news stories on BioPortfolio along with dozens of Testing Immune Hotspots Predict Risk That Breast Cancer Clinical Trials and PubMed Articles about Testing Immune Hotspots Predict Risk That Breast Cancer for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Testing Immune Hotspots Predict Risk That Breast Cancer Companies in our database. You can also find out about relevant Testing Immune Hotspots Predict Risk That Breast Cancer Drugs and Medications on this site too.

Showing "Testing immune hotspots predict risk that breast cancer" PubMed Articles 51–75 of 41,000+

Validation of a genetic risk score for Arkansas women of color.

African American women in the state of Arkansas have high breast cancer mortality rates. Breast cancer risk assessment tools developed for African American underestimate breast cancer risk. Combining African American breast cancer associated single-nucleotide polymorphisms (SNPs) into breast cancer risk algorithms may improve individualized estimates of a woman's risk of developing breast cancer and enable improved recommendation of screening and chemoprevention for women at high risk. The goal of this stud...

Assessing Breast Cancer Risk with an Artificial Neural Network

Objectives: Radiologists face uncertainty in making decisions based on their judgment of breast cancer risk. Artificial intelligence and machine learning techniques have been widely applied in detection/recognition of cancer. This study aimed to establish a model to aid radiologists in breast cancer risk estimation. This incorporated imaging methods and fine needle aspiration biopsy (FNAB) for cyto-pathological diagnosis. Methods: An artificial neural network (ANN) technique was used on a retrospectively co...

Levothyroxine use and the risk of breast cancer: a nation-wide population-based case-control study.

To investigate whether the use of levothyroxine was associated with breast cancer risk.

Five Common Functional Polymorphisms in microRNAs and Susceptibility to Breast Cancer: An Updated Meta-Analysis.

microRNAs (miRNA) play a key role in the pathogenesis of breast cancer (BC) as regulators of tumor-associated genes, and understanding their polymorphisms is critical to the control of breast carcinogenesis. Thus, the present study explored the association between five common functional polymorphisms in miRNAs (i.e., miRNA-196a2C>T, rs11614913; miRNA-146aG>C, rs2910164; miRNA-423C>A, rs6505162; miRNA-608G>C, rs4919510; miRNA-27aC>T, rs895819) and the risk of BC.

Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis.

Several studies have reported a high risk of local disease recurrence (LR) and locoregional disease recurrence (LRR) in patients with breast cancer after neoadjuvant chemotherapy (NCT) and breast-conserving therapy (BCT). The objective of the current study was to identify potential risk factors for LR and LRR after NCT and BCT.

Pre-diagnostic changes in body mass index and mortality among breast cancer patients.

We investigated whether changes in body mass index (BMI) before a breast cancer diagnosis affected mortality and whether trajectories more accurately predict overall mortality compared to a single measure of BMI.

Breast cancer prognosis signature: linking risk stratification to disease subtypes.

Breast cancer is a very complex and heterogeneous disease with variable molecular mechanisms of carcinogenesis and clinical behaviors. The identification of prognostic risk factors may enable effective diagnosis and treatment of breast cancer. In particular, numerous gene-expression-based prognostic signatures were developed and some of them have already been applied into clinical trials and practice. In this study, we summarized several representative gene-expression-based signatures with significant progn...

Reproducible automated breast density measure with no ionizing radiation using fat-water decomposition MRI.

Increased breast density is a significant independent risk factor for breast cancer, and recent studies show that this risk is modifiable. Hence, breast density measures sensitive to small changes are desired.

Use of antipsychotics and risk of breast cancer: A Danish nationwide case-control study.

Some antipsychotics increases prolactin levels, which might increase the risk of breast cancer. Existing evidence is conflicting and based on sparse data, especially for the increasingly used second-generation antipsychotics. We conducted a nationwide case-control study of the association between antipsychotic use and incident breast cancer.

Only estrogen receptor "positive" is not enough to predict the prognosis of breast cancer.

Beginning in 2018, biomarkers including estrogen receptor (ER) status were incorporated in the 8th AJCC staging system. ER expression levels were not considered in these changes. We hypothesized that the levels of ER expression could affect the prognosis of breast cancer.

Detection and differential diagnosis of cancer relapse using circulating tumor DNA profiling in a patient with synchronous breast and rectal cancer.

In Chinese women, breast and colorectal cancers are highly prevalent. In the early stage, the primary treatment for these cancers is surgical resection. However, many patients develop a metastatic recurrence. Thus, tools that help estimate the risk of recurrence are critical. Although synchronous breast and rectal cancer is uncommon, estimating recurrence risk is even more challenging in patients with two histologically distinct malignancies.

Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.

The Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Working Group is a consortium of National Cancer Institute-sponsored investigators who use statistical and simulation modeling to evaluate the impact of cancer control interventions on long-term population-level breast cancer outcomes such as incidence and mortality and to determine the impact of different breast cancer control strategies. The CISNET breast cancer models have been continuously funded since 2000. The models have...

rs11615 Polymorphism Increases Susceptibility to Breast Cancer: A Meta-Analysis of 4547 Individuals.

Excision repair cross-complementation group 1 (ERCC1), a DNA repair protein, is vital for maintaining genomic fidelity and integrity. Despite the fact that a mounting body of case-control studies has concentrated on investigating the association of the rs11615 polymorphism and breast cancer risk, there is still no consensus on it. We conducted the current meta-analysis of all eligible articles to reach a much more explicit conclusion on this ambiguous association. A total of seven studies involving 2354 br...

Breast Cancer Risk Evaluation by Utilizing Gail Model and Association between Breast Cancer Risk Perception with Early Diagnosis Applications among Midwives and Nurses Working in Primary Health Services.

The present study was performed to detect cancer risk of the midwifes and nurses playing central role in raising awareness in the society using Gail's model.

High frequency of pathogenic non-founder germline mutations in and in families with breast and ovarian cancer in a founder population.

Pathogenic founder mutations (c.4035delA, c.5266dupC) contribute to 3.77% of all consecutive primary breast cancers and 9.9% of all consecutive primary ovarian cancers. Identifying germline pathogenic gene variants in patients with primary breast and ovarian cancer could significantly impact the medical management of patients. The aim of the study was to evaluate the rate of pathogenic mutations in the 26 breast and ovarian cancer susceptibility genes in patients who meet the criteria for testing and to c...

Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.

Several proteins involved in immune regulation and the relationship among these, the tumor microenvironment, and clinical outcomes of eribulin treatment were evaluated in advanced or metastatic breast cancer patients.

Intake of bean fiber, beans, and grains and reduced risk of hormone receptor-negative breast cancer: the San Francisco Bay Area Breast Cancer Study.

High dietary fiber intake has been associated with reduced breast cancer risk, but few studies considered tumor subtypes defined by estrogen receptor (ER) and progesterone receptor (PR) status or included racial/ethnic minority populations who vary in their fiber intake. We analyzed food frequency data from a population-based case-control study, including 2135 breast cancer cases (1070 Hispanics, 493 African Americans, and 572 non-Hispanic Whites (NHWs)) and 2571 controls (1391 Hispanics, 557 African Americ...

Association of BRCA2 K3326* With Small Cell Lung Cancer and Squamous Cell Cancer of the Skin.

Most pathogenic mutations in the BRCA2 gene carry a high risk of hereditary breast and ovarian cancer (HBOC). However, a stop-gain mutation, K3326* (rs11571833), confers risk of lung cancer and cancers of the upper-aero-digestive tract but only a modest risk of breast or ovarian cancer. The Icelandic population provides an opportunity for comprehensive characterization of the cancer risk profiles of K3326* and HBOC mutations because a single mutation, BRCA2 999del5, is responsible for almost all BRCA2-relat...

BRCA1 and BRCA2 5' non-coding region variants identified in breast cancer patients alter promoter activity and protein binding.

The widespread use of next generation sequencing for clinical testing is detecting an escalating number of variants in non-coding regions of the genome. The clinical significance of the majority of these variants is currently unknown, which presents a significant clinical challenge. We have screened over 6000 early-onset and/or familial breast cancer cases collected by the ENIGMA consortium for sequence variants in the 5' non-coding regions of breast cancer susceptibility genes BRCA1 and BRCA2, and identifi...

Stop eating plastic, molecular signaling of bisphenol A in breast cancer.

Breast cancer is the second most common fatal cancer in women. Developing a breast cancer is a multi-factorial and hormonal-dependent process, which may be triggered by many risk factors. An endocrine disrupting substance known as bisphenol A (BPA), that is used greatly in the manufacture of plastic products, was suggested as a possible risk factor for developing breast cancer. BPA has a strong binding affinity to non-classical membrane estrogen receptors like estrogen-related and G protein-coupled (GPER) r...

The Significance of the Stromal Response in Breast Cancer: An Immunohistochemical Study of Myofibroblasts in Primary and Metastatic Breast Cancer.

Gene expression profiling of breast cancer has demonstrated the importance of stromal response in determining the prognosis of invasive breast cancer. The host response to breast cancer is of increasing interest to pathologists and may be a future focus for novel pharmacological treatments.

Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.

Risk factors for breast cancer relapse are well-known, such as large tumour size or lymph node involvement. The aim of our study was to analyse the influence of bone mineral density, fractures and bisphosphonate or vitamin D prescription on 10 years' breast cancer outcome.

A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.

BRCA1 inherited mutation carriers face a lifetime risk of 72% to develop breast cancer and a percentage of 44% risk for ovarian cancer.

Breast Cancer Risk factor awareness and utilization of screening program: A cross-sectional study among women in the Northern Emirates.

Breast cancer is the principal cause of cancer deaths among women worldwide. Among Emirati females, breast cancer ranked first accounting for 23.1% of the total cancers. Around 58% of the cases occurred were reported from northern emirates. United Arab Emirates is having higher percentage of expat female population than Emirati women. There is lack of data regarding the knowledge and attitude about breast cancer in this mixed population.

Association of RETN and CAP1 SNPs, Expression and Serum Resistin Levels with Breast Cancer in Mexican Women.

Breast cancer is the most common cancer in women worldwide. Approximately 70% of female breast cancer patients have a body mass index (BMI) >25. In obesity, adipose tissue secretes additional resistin, which prompts a proinflammatory effect through its action on adenylate cyclase-associated protein 1 (CAP1). Several studies have associated the RETN gene single nucleotide polymorphism (SNP) rs1862513 (-420C

Quick Search